QCDx LLC is a medical company based in Farmington, CT, dedicated to providing innovative solutions for the detection and profiling of rare cells in the bloodstream. Their advanced technology, the RareScope system, allows for enrichment-free profiling and isolation of rare circulating tumor cells (CTCs) through 3-D optical tomography, enabling real-time cancer intelligence and precision diagnosis. With a focus on improving patient outcomes and quality of life, QCDx aims to optimize treatment, monitor therapy, characterize metastasis, and assess treatment toxicity.
Utilizing their novel MultiFluor multiplex immunofluorescent probes, QCDx's RareScope platform offers rapid CTC profiling with 12 biomarkers in intact live cells, providing personalized and real-time intelligence on treatment-specific markers. This technology has applications in cancer diagnostics, cancer research, and the pharmaceutical industry, supporting all stages of drug discovery and clinical trials. With the ability to visualize cells morphologically intact and live, QCDx's RareScope system offers enrichment-free rare cell detection, deep characterization, single-cell isolation, and 3D-culture of cells under continual visualization.
Generated from the website